Is Artelo Biosciences, Inc. (ARTL) a Buy, Sell, or Hold?
Artelo Biosciences, Inc.
NASDAQ:ARTL
$1.15 USD
-$0.01 (-0.86%)
- Volume
- 368.63K
- Average Volume
- 1.72M
- Market Capitalization
- $2.68M
- P/E Ratio
- -0.12
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $50.90
- Year Low
- $0.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.79
| Source | Headline |
|---|---|
|
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to vote globenewswire.com - 2026-07-14 08:47:00 |
|
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building on interim findings from CAReS Phase 2 clinical study which demonstrated improvements in body weight, lean body mass and activity levels SOLANA BEACH, Calif. globenewswire.com - 2026-07-13 09:02:00 |
|
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer globenewswire.com - 2026-07-13 09:02:00 |
|
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain globenewswire.com - 2026-07-01 08:42:00 |
|
Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 Multi-omics analyses identifies linoleic acid as a critical fatty acid which is modulated by ART26.12 globenewswire.com - 2026-06-30 08:57:00 |
|
Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics Profile AI Aided Target Engagement Research Advancing Development of Novel Biomarkers SOLANA BEACH, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced two presentations of clinical and translational research findings supporting the development of ART26.12, the Company's proprietary selective fatty acid binding protein 5 (FABP5) inhibitor, at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium. globenewswire.com - 2026-06-29 08:45:00 |
|
Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London Artelo's lead medicinal chemist reveals findings at the Royal Society of Chemistry-BMCS/DMDG Medicinal Chemistry Conference in London globenewswire.com - 2026-06-10 07:38:00 |
|
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the quarter ended March 31, 2026, and outlined upcoming milestones across its portfolio. globenewswire.com - 2026-05-14 16:05:00 |
|
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
SOLANA BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced details of a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5 (FABP5) inhibitor platform. ScienceMachine's platform, which leverages cutting-edge AI agent technology, is built to interrogate large biological datasets in a fraction of the time and cost of traditional methods. globenewswire.com - 2026-04-28 08:25:00 |
|
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year globenewswire.com - 2026-04-20 07:50:00 |
